Singapore markets close in 4 hours 12 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
66.77-0.96 (-1.42%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close67.73
Bid0.00 x 1200
Ask0.00 x 1200
Day's range66.60 - 67.96
52-week range56.56 - 73.34
Avg. volume6,233,656
Market cap83.717B
Beta (5Y monthly)0.42
PE ratio (TTM)16.35
EPS (TTM)4.09
Earnings date28 Oct 2021
Forward dividend & yield2.84 (4.19%)
Ex-dividend date14 Sep 2021
1y target est76.26
  • Zacks

    Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More

    Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.

  • Zacks

    Healthcare ETFs in Focus as Q3 Earnings Unfold

    The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

  • Motley Fool

    2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays

    With that in mind, let's look at two healthcare stocks that have performed poorly over the past year but have a chance to bounce back big: Gilead Sciences (NASDAQ: GILD) and Incyte (NASDAQ: INCY). Biotech giant Gilead Sciences is still feeling the aftereffects of a regulatory setback related to filgotinib, its potential medicine for rheumatoid arthritis. The company hoped that it would become a blockbuster product, but the U.S. Food and Drug Administration (FDA) had other plans.